Atlas Trials

A Study to Investigate the Efficacy, Safety and Tolerability of Four Different Doses of BI 409306 Compared to Placebo Given for 12 Weeks in Patients With Schizophrenia on Stable Antipsychotic Treatment.

Clinical trial NCT02281773 · COMPLETED

Trial details

NCT number
NCT02281773
Sponsor
Boehringer Ingelheim
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Schizophrenia
Start date
2014-11-10
Primary completion
2016-05-26
Enrollment
518

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.